We performed a multicenter study in order to validate the concept that a simple CGA can identify elderly DLBCL non-fit patients in whom curative treatment is not better then palliation and to analyse potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria.
INTRODUCTION
In the last few years Comprehensive Geriatric Assessment (CGA) was recognized as an essential tool for clinicians that manage elderly people affected by aggressive diseases [1] . The definition of elderly is still a matter of debate in oncology. In patients with lymphoma the age limit more frequently used to discriminate between younger and older patients is 65 [2] .
It is no longer acceptable to exclude patients from intensive treatment with curative intent only on the basis of chronological age. Aging is highly individualized in terms of life expectancy, functional reserve and social support and treatment plans need to account for this diversity that can be better evaluated by a multidimensional approach [3] .
Diffuse large B cell lymphoma (DLBCL) represents a typical example of neoplastic disease that can be cured with an aggressive program. The majority of these patients are over the age of 60 years and the steady improvement of life expectancy will probably further increase their number in the future [2] . Therefore, trying to improve the survival of this category of patients represents one of the major challenges for the haematologists. CGA proved to be an effective method to identify elderly DLBCL patients able to tolerate intensive treatment with curative intent, achieving an outcome similar to the one of younger patients [4] .
However about one half of the elderly patients cannot benefit from a curative approach and their prognosis is still very poor independently of the treatment received.
Although broad agreement exists among oncologists on the different aspects of geriatric assessment and on the instruments to use for evaluating elderly peoples performance, the categories of elderly patients that need to be identified are still debated and the interpretation of the results of CGA tests has not been standardized yet . In particular, since new and very effective treatments with a better tolerability profile like anti-CD20 monoclonal antibodies have become available, the attempt to better define non-fit patients according to the extent of their limitations could help clinicians to better tailor treatment trying to improve the efficacy of therapies in this patient category.
Therefore the FIL launched a multicenter prospective study to verify our previous results in a broader population of DLBCL patients with the same clinical characteristics and to assess the potential usefulness of a comprehensive geriatric assessment that further divides non-fit patients in two different levels according to the severity of their unfitness.
PATIENTS AND METHODS
All consecutive patients with diffuse large B cell lymphoma aged more than 69 years seen in 13
Hematology departments of the Italian Lymphoma Foundation (FIL) were recorded during one year. CGA was performed during staging procedures after written informed consent through the application of the following instruments: 1) age>80 years; 2) comorbidity score according to the Cumulative Illness Rating Score for Geriatrics (CIRS-G) [5] and evaluated in all the organs/systems as follows: no problem-0, mild problem (may require treatment)-1, moderate disability or morbidity (treatment required)-2, severe, constant, significant disability/''uncontrollable'' chronic problems-3, extremely severe disability, immediate treatment required/end organ failure/severe impairment in function-4; 3) activity of daily living (ADL), that is, loss in any activity, including bathing, dressing, toileting, transferring, feeding, and continence [6] ; 4) instrumental activity of daily living (IADL), an indirect evaluation of functional abilities necessary for independent living through caregivers interview [7] . Patients were classified in the category of ''fit'' patients if they had all of the following conditions: age <80, no limitations in ADL and IADL scores: ADL score 6 and IADL score 8, CIRS-G: no grade 3-4 comorbidities (hematological comorbidities were not investigated) and less than 5 grade 2 comorbidities. Patients were classified as ''unfit" if they had all of the following conditions: age > 79, no limitations in ADL and IADL scores: ADL score 6 and IADL score 8, CIRS-G: no grade 3-4 comorbidities and less than 5 grade 2 comorbidities. In addition patients aged <80 with ADL score of 5 and/or IADL score of 6-7, and/or CIRS-G: no grade 3-4 comorbidities and 5 to 8 grade 2 comorbidities were also classified as "unfit". All other patients who did not meet the criteria for fit and unfit patients were classified as ''frail'' [8] (Table I) rituximab as a single agent, corticosteroids alone, oral monochemotherapy or anthracycline-based cycles at a relative dose intensity less than 70%, which were all defined as palliative therapy.
The purpose of the study was to evaluate the outcome of the consecutive patients both considering the intensity of treatment received and the results of CGA assessment.
Statistical analyses were performed using Prism software (GraphPad Software, La Jolla, Calif).
The overall survival (OS) time was computed from the initiation of therapy to the last visit that the patient was known to be alive or death from any cause and was evaluated according to the Kaplan-Meier method [9] . The characteristics of the subgroups of patients subdivided according to the type of treatment received and to CGA categorization were compared using Fisher exact test, Student t test, and Mann-Whitney statistics, as appropriate. Log-rank analysis was used to compare actuarial survival curves [10] .The multivariate analysis of survival was performed using the Cox proportional hazard ratio (HR) [11] and 95% confidence interval (CI), taking into account all variables that had been shown to be significantly associated with survival in the univariate analysis.
RESULTS
From September 2009 to August 2010, 177 patients aged more than 69 and affected by DLBCL were consecutively registered and 173 of them had fully evaluable data to be considered for the present study. According to CGA, 79 (46%) patients were classified as ''fit'', 28 (16%) as "unfit" and 66 (38%) as "frail". Two fit, one unfit and 1 frail patients were lost to follow up. Among unfit patients, 50% were aged more than 79 without any other limitation, 15% had one or two limitation in IADL only, 23% in IADL and ADL and 12% in IADL with more than 4 comorbidities of grade 2.
Among frail patients 13% were aged more than 79 and unfit, 15% had one or more comorbidities of Considering patients treated with curative intent overall, the survival of fit patients was significantly better than survival of non-fit patients (88% vs 56%) (p 0.0001).
Within the single CGA categories, the 2-year overall survival of patients treated with curative or palliative intent was 88% vs 25% (p 0.0001) in fit , 75% vs 45% (p 0.32) in unfit, and 44% vs 39% (p 0.75) in frail patients respectively (Figure 2 ).
The rate of non hematologic toxicity of grade > 2 was not significantly different among patients treated respectively with curative or palliative intent (45% vs 38%; p 0.3). Lymphoma was the main cause of death in both treatment groups.
At univariate analysis, age, IPI, CGA, ADL, IADL, CIRS-G, treatment approach (curative vs palliative) and treatment dose-intensity (cut-off 70%) were significantly associated with overall survival. Within a multivariate analysis only IPI and CGA maintained their strong association with overall survival (Table IV) .
DISCUSSION
The results of our study confirm that CGA is a strong independent predictor of overall survival [12, 13] and can be usefully applied to the treatment decision in elderly patients with DLBCL. We adopted age 70 as the lower limit of clinical senescence since the prevalence of age-related changes is represented by an almost flat line up to this age and increases sharply with older age [3, 14] .
We used a modified score originally proposed by Balducci [3] that we have validated in a small population of elderly DLBCL patients [4] and that Spina et al. already proposed in a modified version. The primary aim was to try to further divide the category of frail patients in order to modulate treatment intensity. A fully standardized geriatric assessment tool is not yet available.
Therefore any choice in the subdivision of the geriatric categories is somewhat arbitrary. However
The same results were obtained in a recent study by Marchesi et al who used a similar simplified CGA [24] . In our paper frail patients had more frequently worse IPI score and stage B than fit patients, although the difference was not significant; however significant better survival of fit compared to frail intensively treated patients was evident both in the subgroup of low and high IPI score, and in the subgroup of A and B stage, eliminating possible bias (data not shown).
Compared to frail patients the outcome of unfit patients was not significantly different. However, there was a clear trend to a better survival, especially in the subgroup treated with curative intent. was used by the French group in elderly patients aged over 80 years without any other CGA parameter selection, obtaining a good compromise between efficacy and safety [18] . The combination of a lower dose of immunochemotherapy with a biologic drug could also be a valid alternative to be tested in a clinical trial.
In conclusion the CGA used in our study proved to be an efficient method to identify elderly DLBCL patients who can benefit from a curative approach with anthracycline-containing immunochemotherapy. It further suggests the potential usefulness of identifying different risk groups in the category of non-fit patients, by showing that a proportion of unfit patients exists who could obtain significant benefit when treated with curative intent. Therefore, new risk adapted strategies of treatment through modulated-intensity programs could reduce the difference of survival between fit and unfit patients and clinical trials in this setting should be planned. Palliation seems the best choice for frail patients and improvement of the supportive care is the only effort that could be proposed in this category of patients. Abbreviations: HR, hazard ratio; CI, confidence interval
